SOM230 is an FDA-approved drug (in 2012, for the treatment of Cushing's pituitary tumours) that, despite inducing hyperglycaemia, does not generate any toxicity (Schmid, 2008; Chan et al, 2012; Henry et al, 2013), unlike translation mTOR inhibitors such as RAD001 (Everolimus® Novartis). Here, MTOR is linked to Hyperglycemia.